Genomic/Proteomic PTB Network: UAB Clinical Core Center

基因组/蛋白质组 PTB 网络：UAB 临床核心中心

• 批准号: 6943811
• 负责人: WILLIAM Walton ANDREWS
• 金额: $ 33.1万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6943811
• 关键词: biomarker; biotechnology; clinical research; clinical trials; cooperative study; cytokine; drug screening /evaluation; functional /structural genomics; gene expression; genetic markers; human genetic material tag; human pregnant subject; human subject; human therapy evaluation; patient oriented research; pregnancy disorder chemotherapy; premature infant human; premature labor; progesterone; proteomics; women' s health

DESCRIPTION (provided by applicant): Preterm birth remains the leading cause of perinatal morbidity and mortality, the rate of preterm birth continues to increase, and effective interventions to prevent preterm birth remain illusive. Investigators in the Center for Research in Women's Health at our institution have provided strong clinical research leadership in this area for 25 years. We have successfully acquired millions of dollars in federal funding to conduct clinical studies designed to improve our understanding of the pathophysiology of preterm birth as well as to test many potential interventions in prospective randomized trials. The productivity of our group has resulted in hundreds of publications in the area of preterm birth and its prevention. Our excellence in performing high quality well-designed clinical trials is widely known. Germane to this application is our particular strength and success in performing multi-center trials and providing a leadership role in research networks including the NICHD Maternal-Fetal Medicine Units Network in which we have been a participating institution for nearly 15 years. Indeed, UAB was ranked first in overall performance among the 14 centers in this Network in the most recent objective ranking of member institutions. Thus, we believe that we are particularly well-positioned, not only to effectively participate, but also to provide leadership as a Clinical Core Center in the proposed Genomic and Proteomic Network. In this application, we will describe in detail our extremely successful clinical research facilities and infrastructure. We will also emphasize our well-documented strengths including patient accrual and retention, high-quality data acquisition and entry, rapid ramp-up to initiate new trials, protocol adherence, analysis and publication productivity, and collaborative success in protocol development and implementation in the NICHD MFMU Network which appears to be a model upon which the proposed new network is based. We believe that our enthusiasm and commitment to this project will be evident and we believe that our qualifications will be very competitive for consideration.

描述（申请人提供）：早产仍然是围产期发病和死亡的主要原因，早产率持续增加，预防早产的有效干预措施仍然不明确。 25 年来，我们机构女性健康研究中心的研究人员在该领域发挥了强大的临床研究领导作用。我们已成功获得数百万美元的联邦资金来开展临床研究，旨在提高我们对早产病理生理学的理解，并在前瞻性随机试验中测试许多潜在的干预措施。我们团队的生产力已在早产及其预防领域发表了数百篇出版物。我们在执行高质量、精心设计的临床试验方面的卓越表现是众所周知的。与此应用相关的是我们在执行多中心试验以及在研究网络（包括 NICHD 母胎医学单位网络）中发挥领导作用方面的独特优势和成功，近 15 年以来，我们一直是该网络的参与机构。事实上，在最近的成员机构客观排名中，UAB 的整体表现在该网络的 14 个中心中名列第一。因此，我们相信，我们处于特别有利的位置，不仅可以有效参与，而且可以作为拟议的基因组和蛋白质组网络中的临床核心中心发挥领导作用。在此申请中，我们将详细描述我们极其成功的临床研究设施和基础设施。我们还将强调我们有据可查的优势，包括患者应计和保留、高质量的数据采集和输入、快速启动新试验、方案遵守、分析和出版生产力，以及方案开发和实施方面的协作成功。 NICHD MFMU 网络似乎是提议的新网络所基于的模型。我们相信我们对这个项目的热情和承诺将是显而易见的，我们相信我们的资格将非常有竞争力。